UCB Articles
Tally of NCEs in 2001 lends credence to talk of R&D productivity
21 January 2002
UCB to post 20% profit growth in 2001
12 December 2001
UCB opens new pharma R&D building
16 November 2001
Xyzal launched in UK
2 October 2001
Stock Commentary - Europe
20 September 2001
UCB expands deal with Gene Logic
7 September 2001
UCB's Xyzal cleared for marketing in EU
31 August 2001
Belgium's UCB closing Japanese factory
31 August 2001
Pfizer's Zyrtec-D 12-Hour approved in USA
16 August 2001
Update: UCB 1st-half pharma turnover leaps 31%
31 July 2001
UCB 1st-half pharma sales leap 31%
30 July 2001
UCB 1st-half pharma sales leap 31%
27 July 2001
Update - Pfizer second-quarter net income leaps 31%
18 July 2001
US FDA discusses third-party OTC switch call
25 June 2001
Good start to 2001 for UCB pharma
15 June 2001
Galapagos and UCB sign allergy deal
11 May 2001
UCB profits up 23% in 2000
11 April 2001
New world market forecasts from DR
6 April 2001
Stock Commentary - Europe
5 April 2001
Sepracor files NDA for norastemizole
13 March 2001
UCB 2000 turnover increases 20%
20 February 2001
BioFocus wins new contracts
8 February 2001
UCB raises R&D spend 25% in 2001
11 January 2001
Healthy harvest of New Chemical Entities in 2000
2 January 2001
Pfizer forecasts strong revenue growth in 2001-2002 at R&D meeting
14 December 2000
UCB's Keppra launch plans following European Union approval
19 October 2000
UCB's Keppra OKed in Europe for epilepsy
5 October 2000
First-half 2000 net income shoots up 121.7% at Italy's Recordati
28 September 2000
UCB reports 27% growth in pretax profit
31 July 2000
UCB's Keppra backed by CPMP
31 July 2000
US HMO wins price cuts from S-P, Aventis
14 July 2000
Pfizer leads 1st-qtr US physician detailing
11 July 2000
UCB Pharma sees favorable 2000
21 June 2000
Stock Commentary Europe
15 June 2000
Pfizer/UCB battle with S-P over Zyrtec
26 May 2000
Stock Commentary Europe
27 April 2000
UCB gains Swiss approval for Keppra
12 April 2000
Good second-half 1999 boosts UCB earnings
3 April 2000
French genomics firm Genfit takes off
3 April 2000
Aventis takes on US antihistamine market with once-daily Allegra
29 February 2000
Stock Commentary Europe
17 February 2000
UCB pharma sales up 19% for 1999
9 February 2000
Pharma industry warned that mergers not a guarantee for success
2 February 2000
Stock Commentary Europe
27 January 2000
Stock Commentary Europe
20 January 2000
Boeh Ing makes hostile bid for Japan's SSP
18 January 2000
UCB acquires drug unit of Fujirebio
11 January 2000
UCB expecting 20% earnings rise for 1999
15 December 1999
UCB forecasts $200m Keppra sales
9 December 1999
First approval for UCB Pharma's Keppra
2 December 1999
UCB's piracetam approved in Japan
25 November 1999
Daiichi Pharma sales growth slower; Harmokisan approval delayed
15 November 1999
Stock Commentary Europe
28 October 1999
French city takes new role in pharma R&D
11 October 1999
Another research partnership for UCB
8 October 1999
Gene Logic & UCB sign database alliance
27 September 1999
UCB Pharma's levetiracetam, Phase III data show efficacy in epilepsy
14 September 1999
UCB Pharma names president
5 August 1999
Belgium's UCB boosted by sales of Zyrtec
5 August 1999
Alza Corp to push Ditropan sales
23 July 1999
GW, S-P push steroids for allergic rhinitis
7 July 1999
Second FDA rebuke for Sepracor over Xopenox
15 June 1999
UCB licenses key drug patents from Sepracor
3 June 1999
Alza's Ditropan XL vs immediate-release form
28 May 1999
UCB boosts 1998 operating profit 28%
23 April 1999
Stock Commentary Europe
22 April 1999
Stock Commentary Europe
31 March 1999
Stock Commentary Europe
29 March 1999
Stock Commentary Europe
18 February 1999
Profits climb 30% at Belgium's UCB
9 February 1999
UCB confident on 1998 results
18 January 1999
UCB Buys R&D operations of CytoMed
29 October 1998
UCB Expanding Activities In Poland
23 October 1998
UCB Upgrades Zyrtec Japan Sales Expectations
7 October 1998
Stock Commentary Tokyo
17 September 1998
Stock Commentary Europe
17 September 1998
Alza Boosts Ditropan XL Sales Effort
24 August 1998
Review Of US Second Qtr & Implications For Euro Firms
20 August 1998
Pharma Sales Soften Blow Of Asian Crisis At UCB
3 August 1998
UCB's Zyrtec Approved In Japan
7 July 1998
Merck, Pfizer Lead Charge Up Global Rankings
7 July 1998
UCB Confident Profits Will Keep Growing
16 June 1998
Belgium's UCB Reviews Research
15 June 1998
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
